Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)
11.08
+0.05 (0.45%)
May 13, 2025, 3:04 PM CST
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Preparation | 2.98B |
Log In |
Log In |
Log In |
Log In |
Preparation Growth | -7.21% |
Log In |
Log In |
Log In |
Log In |
API | 1.31B |
Log In |
Log In |
Log In |
Log In |
API Growth | -51.09% |
Log In |
Log In |
Log In |
Log In |
Contract Development and Manufacturing Operations | 966.95M |
Log In |
Log In |
Log In |
Log In |
Contract Development and Manufacturing Operations Growth | -10.80% |
Log In |
Log In |
Log In |
Log In |
Other | 191.79M |
Log In |
Log In |
Log In |
Log In |
Other Growth | 0.35% |
Log In |
Log In |
Log In |
Log In |
Trypsin and Other | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Europe | 2.62B |
Log In |
Log In |
Log In |
Log In |
Europe Growth | -29.87% |
Log In |
Log In |
Log In |
Log In |
United States | 1.28B |
Log In |
Log In |
Log In |
Log In |
United States Growth | -7.90% |
Log In |
Log In |
Log In |
Log In |
Other Countries | 1.12B |
Log In |
Log In |
Log In |
Log In |
Other Countries Growth | -13.01% |
Log In |
Log In |
Log In |
Log In |
China | 412.43M |
Log In |
Log In |
Log In |
Log In |
China Growth | -35.83% |
Log In |
Log In |
Log In |
Log In |
Hong Kong | 18.10M |
Log In |
Log In |
Log In |
Log In |
Hong Kong Growth | -82.43% |
Log In |
Log In |
Log In |
Log In |
International | - |
Log In |
Log In |
Log In |
Log In |
International Growth | - |
Log In |
Log In |
Log In |
Log In |